Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Phase 1 Completed 20 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelTreatment

Summary

Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.

Timeline

Start: 2008-04
Primary completion: 2008-12
Completion: 2008-12

Publications

Wagner F, Thompson R, Kantaridis C, Simpson P, Troke PJ, Jagannatha S, Neelakantan S, Purohit VS, Hammond JL. Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hepatology. 2011 Jul;54(1):50-9. doi: 10.1002/hep.24342.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Filibuvir	Small molecule	450 mg	—
Subject	Filibuvir	Small molecule	700 mg	—

Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.

Summary

Timeline

Publications

Drugs

Indications